SCHEMBL7921065

SCHEMBL7921065

CC(C)(C)[N+]([O-])=Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
KDM4E B2RXH2 1/20 0.37
MAOB P27338 1/20 0.36
AOC3 Q16853 1/20 0.36
KMT2A Q03164 2/20 0.35
EPHX2 P34913 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2D6 P10635 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2152818 0.80 FBP1 (0.49) ALDH1A1LMNAKDM4ETSHRCYP1A2
SCHEMBL15216490 0.77 FBP1 (0.49) ALDH1A1TDP1TSHRHSD17B10CYP1A2
SCHEMBL7922827 0.77 FBP1 (0.49) ALDH1A1TDP1TSHRHSD17B10CYP1A2
SCHEMBL6154484 0.76 PTGS2 (0.51) ALDH1A1MAPTSMN1; SMN2MAOBKMT2A
SCHEMBL19084670 0.76 ALDH1A3 (0.50) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL7926738 0.76 ALDH1A1 (0.48) ALDH1A1MAPTL3MBTL1TDP1TSHR
SCHEMBL15216500 0.76 ALDH1A1 (0.48) ALDH1A1MAPTL3MBTL1TDP1TSHR
SCHEMBL6637190 0.75 ADORA2A (0.40) ALDH1A1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL28552488 0.74 FBP1 (0.44) ALDH1A1SMN1; SMN2MAOBKMT2AL3MBTL1
SCHEMBL15216491 0.74 FBP1 (0.44) ALDH1A1SMN1; SMN2MAOBKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6194461-B1 USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-02-27 US disclosed
EP-0945426-A1 NITRONE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-09-29 EP disclosed